Aetna is looking to jettison its Medicare Advantage plans in order to placate antitrust concerns at the Department of Justice over its proposed merger with Humana, and Reuters is reporting at least two companies are competing for that portfolio.

Sources “familiar with the matter” say WellCare and Centene have submitted for bids for plans that cover around 350,000 patients, with a possible sale price of $1 billion.

To read more on the potential sale and how it may affect regulators’ final decision on the Aetna-Humana deal, click on the link below: